EVP/General Counsel Brown sold 38,957 shares (69.5% of holdings) for $6.3M across 7 transactions at prices up to $162.65.
Ryan Edward Brown, EVP and General Counsel of Sarepta Therapeutics, executed 7 separate sales totaling 38,957 shares for $6,296,029.42 on 2024-06-25, reducing his position from 56,086 shares to 17,129 shares. The shares sold at prices ranging from $158.07 to $162.65, with a blended average price of $161.61, near the 52-week high of $163.85. This represents a substantial liquidation of 69.5% of his pre-transaction holdings by an officer with fiduciary responsibilities. While the company achieved strong quarterly revenue of $413.5M and year-over-year growth of 33.3%, it remains unprofitable on a full-year basis with a notably elevated P/E of 878.11. The timing of this multi-tranche sale near the stock's 52-week peak and concurrent with recent strong stock performance (30-day change: +28.0%, 90-day change: +21.4%) merits investor attention regarding executive confidence at current valuations.